Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.32 USD | +3.57% | +3.57% | -35.73% |
Mar. 25 | Finch Therapeutics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Top Premarket Decliners | MT |
Business Summary
Number of employees: 1
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biological Drugs
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 0 | 100.0 % | -87.57% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthew Blischak
CEO | Chief Executive Officer | - | 23-05-15 |
Lance Thibault
DFI | Director of Finance/CFO | 58 | 23-05-15 |
Sonia Timberlake
CTO | Chief Tech/Sci/R&D Officer | - | - |
Matthew Nelson
PRN | Corporate Officer/Principal | - | 21-06-30 |
Michelle L. Rose
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Susan Graf
CHM | Chairman | 52 | 21-04-22 |
Jeffery Smisek
BRD | Director/Board Member | 69 | 17-08-31 |
Chris W. Shumway
BRD | Director/Board Member | 58 | 20-08-31 |
Director/Board Member | 58 | 19-09-24 | |
Christian Lange
BRD | Director/Board Member | 44 | 17-08-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,605,763 | 746,985 ( 46.52 %) | 0 | 46.52 % |
Company contact information
Finch Therapeutics Group, Inc.
75 State Street Suite 100
02109, Boston
+
http://www.finchtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
-35.73% | 3.73M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- FNCH Stock
- Company Finch Therapeutics Group, Inc.